In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Are Share Buybacks a Wise Investment for Biopharma

Executive Summary

Biogen Idec, Genzyme and Amgen have eached announced large share buybacks recently. Wall street smiles on these buybacks and the conventional wisdom suggests they are a tax-efficient way of returning cash to shareholders. But in biopharmaceuticals, there is a downside to these shareholder sweeteners.

You may also be interested in...



EU Pharma Ups Share Buybacks In 2012

Share buybacks are controversial in the biopharma industry, but European pharma companies, facing tough operating environments and pressures on near-term financials, are planning to invest in them in 2012 more than in recent years.

Pharma, Uncertain Of What To Do With Its Cash, Turns To Share Buybacks

Pfizer Inc.'s announcement on Feb. 1 that it plans an enormous, near-term share repurchasing program caught investors' attention and highlighted a persistent, if sometimes muted, ongoing debate in the industry about the best use of its cash.

Can't Say No: Pharma's Addiction to Shareholder Payouts

Having created a shareholder addiction to cash payments, companies are now going to have to make the unpleasant choice between pleasing investors in the short term and building their businesses over the next decade. IN VIVO examines pipeline confidence, patent expirations, and cash flow woes to make some forecasts about the industry's financial health, as well as looking inside the strategies that Big Pharma is currently pursuing.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV002954

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel